MARKET

NURO

NURO

NeuroMetrix
NASDAQ

Real-time Quotes | Nasdaq Last Sale

2.910
-0.250
-7.91%
After Hours: 2.840 -0.07 -2.41% 17:37 04/20 EDT
OPEN
3.160
PREV CLOSE
3.160
HIGH
3.200
LOW
2.840
VOLUME
61.14K
TURNOVER
--
52 WEEK HIGH
5.78
52 WEEK LOW
1.390
MARKET CAP
11.05M
P/E (TTM)
-3.2785
1D
5D
1M
3M
1Y
5Y
NeuroMetrix, Inc. Announces Date for First Quarter 2021 Financial Results Conference Call
WOBURN, Mass., April 15, 2021 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) announced today that it plans to issue its 2021 first quarter financial results before the opening of the market on April 22, 2021. The Company will host a conference call a...
GlobeNewswire · 5d ago
NEUROMETRIX, INC. (NASDAQ:NURO) Files An 8-K Other Events
Apr 15, 2021 (Market Exclusive via COMTEX) -- NEUROMETRIX, INC. (NASDAQ:NURO) Files An 8-K Other Events NeuroMetrix, Inc. ExhibitSEC.gov | Request Rate...
Market Exclusive · 5d ago
BRIEF-NeuroMetrix Filed A Prospectus Supplement To Register The Offer And Sale Of $3.85 Million Of Co's Common Stock
reuters.com · 5d ago
NeuroMetrix Shares Spike Higher; Co Received Notice Of Allowance For U.S. Patent Application Titled 'APPARATUS AND METHOD FOR THE AUTOMATED CONTROL OF TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION BASED ON CURRENT AND FORECASTED WEATHER CONDITIONS'
https://patentcenter.uspto.gov/#!/applications/15990994/ifw/docs
Benzinga · 03/03 16:18
10-K: NEUROMETRIX, INC.
(EDGAR Online via COMTEX) -- ITEM 7. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS You should read the following...
Edgar Online - (EDG = 10Q, 10K) · 01/29 11:11
DJ NeuroMetrix, Inc. CEO Dr. Shai Gozani on Q4 2020 Results -- Earnings Call Transcript >NURO
Dow Jones · 01/29 01:58
NeuroMetrix reports Q4 results
NeuroMetrix (NURO): Q4 net loss of $0.3M.Revenue of $1.8M (+5.9% Y/Y)Shares -5% PM.Press Release
Seekingalpha · 01/28 14:02
BRIEF-NeuroMetrix Reports Q4 And Full Year 2020 Financial Results
reuters.com · 01/28 12:07
More
Forecast
Actual (K USD)
Estimate (K USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of NURO. Analyze the recent business situations of NeuroMetrix through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 1 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average NURO stock price target is 50.00 with a high estimate of 50.00 and a low estimate of 50.00.
EPS
Institutional Holdings
Institutions: 28
Institutional Holdings: 833.91K
% Owned: 21.97%
Shares Outstanding: 3.80M
TypeInstitutionsShares
Increased
1
5.08K
New
3
53.66K
Decreased
1
3.29K
Sold Out
1
34.84K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Medical Equipment, Supplies & Distribution
-0.46%
Healthcare Equipment & Supplies
-0.53%
Key Executives
Chairman/Chief Executive Officer/President/Secretary/Director
Shai Gozani
Chief Financial Officer/Senior Vice President/Treasurer
Thomas Higgins
Senior Vice President
Francis McGillin
Independent Director
David Goodman
Independent Director
Nancy Katz
Independent Director
David Van Avermaete
Declaration Date
Dividend Per Share
Ex-Div Date
03/14/2007
Dividend USD 0.15
03/28/2007
  • All
  • Financials
  • Insiders
More
About NURO
NeuroMetrix, Inc. is a healthcare company combining bioelectrical and digital medicine to address chronic health conditions, including chronic pain, sleep disorders and diabetes. The Company is engaged in the sale of medical equipment, and consumables and accessories. It has two principal product lines: Wearable neuro-stimulation therapeutic devices and Point-of-care neuropathy diagnostic tests. Its products include ADVANCE NCS/EMG System (the ADVANCE System), Quell, SENSUS and DPNCheck. Quell is a wearable device for relief of chronic intractable pain, such as nerve pain due to diabetes and lower back problems. The SENSUS pain therapy device, the technological predecessor to Quell, is a prescription neuro-stimulation device based on transcutaneous electrical nerve stimulation (TENS) for relief of chronic, intractable pain. DPNCheck is a quantitative nerve conduction test. ADVANCE System is a platform for the performance of traditional nerve conduction studies.

Webull offers kinds of Neurometrix Inc stock information, including NASDAQ:NURO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NURO stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading NURO stock methods without spending real money on the virtual paper trading platform.